Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2014 1
2015 3
2016 2
2017 2
2018 1
2020 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?
Baker KF, Isaacs JD. Baker KF, et al. Ann Rheum Dis. 2018 Feb;77(2):175-187. doi: 10.1136/annrheumdis-2017-211555. Epub 2017 Aug 1. Ann Rheum Dis. 2018. PMID: 28765121 Review.
We also present an overview of biologics active against type I and II interferons, including sifalumumab, rontalizumab, anifrolumab and fontolizumab. Emerging strategies to interfere with cellular adhesion processes involved in lymphocyte recruitment are discussed, includi …
We also present an overview of biologics active against type I and II interferons, including sifalumumab, rontalizumab, anifrolumab a …
Interferon α-targeted therapy.
Hanaoka H, Takeuchi T. Hanaoka H, et al. Nihon Rinsho Meneki Gakkai Kaishi. 2013;36(4):181-8. doi: 10.2177/jsci.36.181. Nihon Rinsho Meneki Gakkai Kaishi. 2013. PMID: 23994795 Review. English, Japanese.
There have been developed three agents, IFNalpha-targeted therapy, Sifalimumab, Rontalizumab and NNC 0152-0000-0001. They are anti-IFNalpha monoclonal antibodies that bind to and specifically neutralizes most IFNalpha subtypes, preventing signaling through the type I IFN r …
There have been developed three agents, IFNalpha-targeted therapy, Sifalimumab, Rontalizumab and NNC 0152-0000-0001. They are anti-IF …
Interferon targeted therapies in systemic lupus erythematosus.
Misra DP, Negi VS. Misra DP, et al. Mediterr J Rheumatol. 2017 Mar 28;28(1):13-19. doi: 10.31138/mjr.28.1.13. eCollection 2017 Mar. Mediterr J Rheumatol. 2017. PMID: 32185249 Free PMC article. Review.
Recent therapeutic approaches have involved monoclonal antibodies directly targeting interferon alpha (sifalimumab, rontalizumab) or the use of interferon alpha kinoid to stimulate endogenous production of anti-interferon antibodies in lupus. ...
Recent therapeutic approaches have involved monoclonal antibodies directly targeting interferon alpha (sifalimumab, rontalizumab) or …
Targeting interferons in systemic lupus erythematosus: current and future prospects.
Mathian A, Hie M, Cohen-Aubart F, Amoura Z. Mathian A, et al. Drugs. 2015 May;75(8):835-46. doi: 10.1007/s40265-015-0394-x. Drugs. 2015. PMID: 25940912 Review.
The primary agents that are currently in clinical development to treat SLE via the targeting of interferon pathways are monoclonal neutralising antibodies (Mab) that bind to and neutralise IFN-gamma (AMG 811), IFN-alpha (sifalimumab, rontalizumab and AGS-009) or its recept …
The primary agents that are currently in clinical development to treat SLE via the targeting of interferon pathways are monoclonal neutralis …
Structural basis of the broadly neutralizing anti-interferon-alpha antibody rontalizumab.
Maurer B, Bosanac I, Shia S, Kwong M, Corpuz R, Vandlen R, Schmidt K, Eigenbrot C. Maurer B, et al. Protein Sci. 2015 Sep;24(9):1440-50. doi: 10.1002/pro.2729. Epub 2015 Aug 18. Protein Sci. 2015. PMID: 26099203 Free PMC article.
IFN-alpha has been used to treat infection by hepatitis-virus type C (HCV) and a correlation between hyperactivity of IFN-alpha-induced signaling and systemic lupus erythematosis (SLE), or lupus, has been noted. Anti-IFN-alpha antibodies including rontalizumab have been un …
IFN-alpha has been used to treat infection by hepatitis-virus type C (HCV) and a correlation between hyperactivity of IFN-alpha-induced sign …
Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.
McBride JM, Jiang J, Abbas AR, Morimoto A, Li J, Maciuca R, Townsend M, Wallace DJ, Kennedy WP, Drappa J. McBride JM, et al. Arthritis Rheum. 2012 Nov;64(11):3666-76. doi: 10.1002/art.34632. Arthritis Rheum. 2012. PMID: 22833362 Free article. Clinical Trial.
The safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of rontalizumab, a humanized IgG1 monoclonal antibody that neutralizes IFNalpha, were assessed in a phase I dose-escalation study of single and repeat doses of rontalizumab in adults with mil …
The safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of rontalizumab, a humanized IgG1 monoclonal antibody that …
A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE).
Kalunian KC, Merrill JT, Maciuca R, McBride JM, Townsend MJ, Wei X, Davis JC Jr, Kennedy WP. Kalunian KC, et al. Ann Rheum Dis. 2016 Jan;75(1):196-202. doi: 10.1136/annrheumdis-2014-206090. Epub 2015 Jun 2. Ann Rheum Dis. 2016. PMID: 26038091 Clinical Trial.
METHODS: Patients with active SLE were randomised (2:1) to 750 mg intravenous rontalizumab every 4 weeks or placebo (Part 1), and 300 mg subcutaneous rontalizumab every 2 weeks or placebo (Part 2). ...Efficacy response rates by BILAG and SRI were similar between …
METHODS: Patients with active SLE were randomised (2:1) to 750 mg intravenous rontalizumab every 4 weeks or placebo (Part 1), and 300 …
Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?
Kalunian KC. Kalunian KC. Lupus. 2016 Sep;25(10):1097-101. doi: 10.1177/0961203316652495. Lupus. 2016. PMID: 27497254
Three biologics that target type I interferons have been tested for their efficacy and safety in active SLE patients; these phase II trials have tested the hypothesis that down-regulation of interferon-regulated gene expression (the interferon signature) lessen the clinical burde …
Three biologics that target type I interferons have been tested for their efficacy and safety in active SLE patients; these phase II trials …
11 results